PSS33 Cost-Utility Analysis (Cua) of First-Line Actinic Keratosis (Ak) Treatments in Finland  by Soini, E. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A609
probabilistic sensitivity analysis suggests that at willingness-to-pay threshold of 
£20-£30,000 per quality-adjusted life year, the probability of early treatment being 
cost-effective is 60%. ConClusions: Panretinal photocoagulation administered 
at the severe NPDR stage is likely to be cost-effective. However, given the limita-
tions of the evidence on current treatments, these results to be interpreted with 
caution. A trial of early versus deferred laser therapy is needed to provide better 
data based on modern treatments.
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objeCtives: CUA of cryosurgery, topical treatments (diclofenac 3% 12 weeks, 
imiquimod 3.75% 6 weeks or 5% 4/8 weeks, ingenol mebutate gel (IMG) 0.015%/
head 3 days or 0.05%/body 2 days), and methyl aminolevulinate + photodynamic 
therapy (MAL+PDT) in the treatment of 25cm2 AK-plague affecting any body 
part. Methods: A sequential probabilistic decision-tree with 2-year time-horizon 
was used to assess the cost-utility (incremental cost-effectiveness ratio, ICER) of 
AK-treatments, and to determine the cost-effectiveness acceptability frontier (CEAF) 
and expected value of perfect information per patient (EVPI) from health care payer 
perspective. In the model, the first-line AK-treatment resulted in complete clearance 
(CC) with or without adverse events (AE), non-CC or AK-recurrence. Non-CC AK was 
retreated with PDT and AK-recurrence was retreated with the previous treatment. 
Incident AK-patients (year 2009, n= 3409, organ transplant patients excluded) were 
identified from the Finnish hospital discharge register to assess AK-related 2-year 
secondary health care costs for patients initiating different treatment regimens. 
Other costs included general practitioner, AE-management, and outpatient drugs 
(5/2014 without VAT; other costs in 2013 value). Quality-adjusted life-years (QALY) 
were based on EQ-5D. Results were discounted with 3% annually. Results: The 
mean per patient 2-year QALYs (costs) were 1.519 (€ 727) for IMG 0.015%, 1.518 (€ 887) 
for MAL+PDT, 1.516 (€ 802) for IMG 0.05%, 1.514 (€ 995) for diclofenac, 1.512 (€ 815) for 
imiquimod 3.75%, 1.511 (€ 707) for imiquimod 5%, and 1.507 (€ 1010) for cryosurgery. 
IMG 0.015% had € 2806/QALY gained ICER against imiquimod 5%, and dominated 
other AK-treatments. IMG 0.05% dominated diclofenac, imiquimod 3.75% and 
cryosurgery, and had € 21,550/QALY gained ICER against imiquimod 5%. MAL+PDT 
had € 32,848/QALY gained ICER against IMG 0.05%. Based on the CEAF, IMG 0.015% 
was the optimal treatment when willingness-to-pay/QALY gained exceeded € 2806. 
The EVPI was € 25/€ 81/€ 211 with the willingness-to-pay of € 0/€ 15,000/€ 30,000 per 
QALY gained. ConClusions: IMG 0.015% was the most cost-effective first-line 
AK-treatment.
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objeCtives: To estimate the cost-effectiveness of ranibizumab 0.5mg pro re nata 
(PRN) compared with aflibercept 2mg bi-monthly in the treatment of visual impair-
ment (VI) due to diabetic macular oedema (DMO) taking a UK health care perspec-
tive. Methods: A Markov model previously reviewed by the National Institute for 
Health and Care Excellence (NICE) was used to simulate the long-term outcomes 
and costs (at 2012 price level) of treating DMO. The health states were defined by 
increments of 10 letters in best-corrected visual acuity (BCVA) with a 3-month 
cycle length. Patients could gain (or lose), at most, 2 health states between two 
cycles. A lifetime time horizon was implemented. Future costs and health out-
comes were discounted at 3.5% per annum. Baseline characteristics, ranibizumab 
effectiveness and adverse events were estimated with data from the RESTORE trial 
(36 months). A published network meta-analysis was used to assess the relative 
effectiveness of ranibizumab to aflibercept. Aflibercept injection frequency was 
calculated with VIVID/VISTA phase III trials. Different utilities were used if the 
treated eye was the better or the worse-seeing eye. Results: Ranibizumab mono-
therapy leads to an incremental gain of 0.05 quality-adjusted life-years (QALY) 
(0.04 from the better-seeing eye and 0.01 from the worse-seeing eye) with a cost 
savings of ₤5,841 relative to aflibercept. Therefore, ranibizumab provides greater 
health gains with lower overall costs than aflibercept. Probabilistic sensitivity 
analysis shows that ranibizumab has a 58% probability of being dominant and 
79% probability of being cost effective compared with aflibercept at a willingness-
to-pay threshold of £20 000/QALY. ConClusions: Ranibizumab is dominant over 
aflibercept in the treatment of VI due to DMO.
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objeCtives: The next generation of artificial vision devices (AVDs), which is cur-
rently tested in clinical trials, has the potential to improve the vision of blind 
patients with retinitis pigmentosa (RP) in a manner that they will be categorized 
as visual impaired but no longer as blind. This unprecedented vision improvement 
will result in a mentionable quality of life gain which poses the question at which 
costs the next generation AVDs are to be regarded as cost-effective. Methods: 
In order to answer this research question a Markov model, with the health states 
blind, visual impaired and death, was developed to simulate and to compare 
the costs and effects of next generation AVDs versus best supportive care (BSC) 
over a lifetime horizon. Health care costs and health utilities for the Markov health 
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objeCtives: To compare ranibizumab with photodynamic therapy (PDT) for 
the treatment of predominantly classic chorodial neovascularization associated 
with age-related macular degeneration (AMD) by means of cost-utility analysis in 
China. Methods: This study compared cost-effectiveness between Ranibizumab 
group (each delivering 0.5 mg of ranibizuamb monthly) and PDT group for the first 
year (short-term) using decision tree model, from third-payer perspective. During 
a 10-year time horizon (long-term), a Markov model was constructed to extrapolate 
effects of treatment beyond clinical trials from a societal perspective (discounted at 
5%). Visual acuity data from the Anti-Vascular Endothelial Growth Factor Antibody 
for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD 
(ANCHOR) trial were applied. Direct-vision-related medical costs were based on 
Clinical Pathway of AMD in China and experts consultation. We performed a lit-
erature review and meta-analysis to estimate the costs related to comorbid states, 
including fall and depression resulting from low vision after suffer from AMD, which 
were rarely inclusive in most previous studies. Informal care costs and utilities data 
were derived from published studies. All costs were adjusted according to 2012 price 
index in China. Probabilistic sensitivity analyses (PSA) were performed to test the 
robustness in structural assumptions and parameter inputs. Cost-effective accepta-
bility curves were performed after a 1000-sample Monte Carlo simulation. Results: 
In short-term model, the incremental cost-effectiveness ratio (ICER) was $81,029/
QALY for ranibizumab compared with PDT. The ICER was reduced to $13,206/QALY 
for a 10-year time frame, when follow-up costs were included. From a societal per-
spective, PSA revealed a 97.75% probability of ranibizuamb being more cost-effective 
than PDT at a threshold of $18,278 per QALY gained (3 times Chinese GDP per capita 
in 2012) in China. ConClusions: Ranibizumab can be a long-term cost-effective 
option for the treatment of AMD compared with PDT from a societal perspective.
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objeCtives: To conduct the cost-utility analysis (CUA) of treatment strategy with 
ranibizumab recommended by the Chinese Clinical Pathway of age-related macu-
lar degeneration (AMD) in China. Methods: Visual acuity data for the as-needed 
dosing regimen with ranibizumab (RBZ-PRN, administrated every month for three 
doses, additional reinjections were determined by physicians’ need) were derived 
from pivotal trials, based on ranibizumab dose of 0.5 mg. Decision tree model and 
Markov model were developed to estimate RBZ-PRN compared with best supportive 
care (BSC) for short and long term. The first year decision tree model from a third-
payer perspective was performed to estimate CUA in short-term. Then a 10-year 
Markov model from a societal perspective were constructed (discounted at 5%) in 
long-term CUA estimation. Resource utilization was obtained from official recom-
mendations in China. The costs of low-vision related disease were extrapolated from 
meta-analysis. Informal care costs and utility values were estimated by published 
studies. The uncertainty was identified in a one-way sensitivity analysis and proba-
bilistic sensitivity analysis (PSA). Cost-effective acceptability curves were obtained 
by a Monte Carlo approach with 1000 repetitions. Results: For RBZ-PRN compared 
with BSC, the incremental cost-effectiveness ratios (ICER) ranged from $90,546/QALY 
for the 1-year time frame to $9,787/QALY for the 10-year time horizon. As indicated 
in the PSA, RBZ-PRN was the optimal strategy in 100% of cases below the willingness 
to pay threshold of $18,278 per QALY gained (3 times Chinese GDP per capita in 2012) 
for the 10-year model. ConClusions: When administered as needed, ranibizumab 
is cost-effective compared with BSC from a societal perspective. In China’s current 
clinical practice, this can be a useful tip for decision-makers who should consider 
cost-effective issues for the treatment of wet-AMD.
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objeCtives: Diabetic retinopathy (DR) is a leading cause of sight loss in people 
of working age. There have been recent developments in laser photocoagulation 
techniques, along with anti-vascular endothelial growth factor drugs for the 
treatment of severe non-proliferative and proliferative DR. The aim of the study 
was to evaluate the cost-effectiveness of panretinal photocoagulation admin-
istered at the severe non-proliferative diabetic retinopathy (NPDR) stage (early 
treatment), compared with waiting until high-risk proliferative (HR-PDR) char-
acteristics (deferred treatment) developed. Methods: A Markov model with a 
30-year time horizon was developed, with clinical pathway options for patients 
presenting with moderate NPDR through to irreversible-severe vision loss and 
blindness (and to death). Once patients entered a post-treatment health state 
they can progress to more severe health states, regress back to earlier stages of the 
disease, persist where they are, or die. NHS and personal social services perspec-
tive was adopted. Transition probabilities were based mainly on data derived from 
the Early Treatment Diabetic Retinopathy Study. Health state utilities, costs and 
complications were based on information from the literature, supplemented by 
expert opinion. Costs and outcomes were discounted at 3.5%. Both deterministic 
and probabilistic sensitivity analyses were conducted. Results: Administering 
panretinal photocoagulation at the severe NPDR stage was more effective and 
less costly than waiting until HR-PDR developed. Sensitivity analyses gave similar 
results, with early treatment continuing to dominate deferred treatment. The 
